JPH0586378B2 - - Google Patents

Info

Publication number
JPH0586378B2
JPH0586378B2 JP59259048A JP25904884A JPH0586378B2 JP H0586378 B2 JPH0586378 B2 JP H0586378B2 JP 59259048 A JP59259048 A JP 59259048A JP 25904884 A JP25904884 A JP 25904884A JP H0586378 B2 JPH0586378 B2 JP H0586378B2
Authority
JP
Japan
Prior art keywords
fragments
igg
cells
fragment
fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59259048A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60185726A (ja
Inventor
Do Karosera Edogarudo
Aruman Jatsuku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANSUCHI MERYUU
Original Assignee
ANSUCHI MERYUU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANSUCHI MERYUU filed Critical ANSUCHI MERYUU
Publication of JPS60185726A publication Critical patent/JPS60185726A/ja
Publication of JPH0586378B2 publication Critical patent/JPH0586378B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP59259048A 1983-12-07 1984-12-07 免疫調整医薬 Granted JPS60185726A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8319568 1983-12-07
FR8319568A FR2556219B1 (fr) 1983-12-07 1983-12-07 Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines

Publications (2)

Publication Number Publication Date
JPS60185726A JPS60185726A (ja) 1985-09-21
JPH0586378B2 true JPH0586378B2 (enExample) 1993-12-10

Family

ID=9294941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59259048A Granted JPS60185726A (ja) 1983-12-07 1984-12-07 免疫調整医薬

Country Status (7)

Country Link
US (1) US4719107A (enExample)
EP (1) EP0147283B1 (enExample)
JP (1) JPS60185726A (enExample)
AT (1) ATE45498T1 (enExample)
CA (1) CA1229791A (enExample)
DE (3) DE3444765A1 (enExample)
FR (1) FR2556219B1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US4925920A (en) * 1987-05-29 1990-05-15 Brigham And Women's Hospital Immunosuppressive polypeptides
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
GB9009106D0 (en) * 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
US5230887A (en) * 1990-07-11 1993-07-27 Immune Network Research Ltd. Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
CA2525917C (en) * 2003-05-16 2017-07-04 Mayo Foundation For Medical Education & Research Compositions and methods including a recombinant human mab that promotes cns remyelination
DE602004031772D1 (de) * 2003-12-04 2011-04-21 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080286819A1 (en) * 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
MX2008012843A (es) * 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
JP4866467B2 (ja) 2007-01-30 2012-02-01 エピバックス インコーポレーテッド 調節性ｔ細胞エピトープ、組成物およびその使用
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2279410B1 (en) * 2008-04-22 2015-11-11 The Rockefeller University Methods of identifying anti-inflammatory compounds
IL286367B2 (en) 2014-05-02 2023-03-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered fc constructs
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
SG11201810465RA (en) 2016-05-23 2018-12-28 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CN117886928A (zh) 2017-01-06 2024-04-16 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2222083B1 (enExample) * 1973-03-22 1976-05-14 Fontaine Michel
FR2267115B1 (enExample) * 1974-04-12 1977-11-10 Merieux Inst
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
DE2853453A1 (de) * 1978-12-11 1980-06-19 Behringwerke Ag Mittel zur therapie von immunkomplexerkrankungen
JPS5821623A (ja) * 1981-07-28 1983-02-08 Tetsuzo Sugizaki 抗原抗体複合体沈着疾患治療剤
JPS5821624A (ja) * 1982-04-06 1983-02-08 Tetsuzo Sugizaki 慢性関節リウマチの治療剤
EP0091760B1 (en) * 1982-04-09 1986-07-02 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Anti immune complex antibody and preparation thereof
US4465670A (en) * 1982-07-23 1984-08-14 Dainippon Pharmaceutical Co., Ltd. Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor

Also Published As

Publication number Publication date
JPS60185726A (ja) 1985-09-21
CA1229791A (fr) 1987-12-01
US4719107A (en) 1988-01-12
EP0147283B1 (fr) 1989-08-16
DE3444765A1 (de) 1985-06-20
EP0147283A3 (en) 1985-08-14
DE147283T1 (de) 1986-04-10
ATE45498T1 (de) 1989-09-15
DE3479398D1 (en) 1989-09-21
EP0147283A2 (fr) 1985-07-03
FR2556219A1 (fr) 1985-06-14
FR2556219B1 (fr) 1987-06-26

Similar Documents

Publication Publication Date Title
JPH0586378B2 (enExample)
Preud'Homme et al. Idiotype‐bearing and antigen‐binding receptors produced by blood T lymphocytes in a case of human myeloma
Schwartz et al. Suppression of immunoglobulin synthesis and secretion by peripheral blood lymphocytes from normal donors.
JPH0198477A (ja) ＩｇＧモノクローナル抗体−生産性ハイブリドマ
Lesslauer et al. T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation
Ralph et al. All classes of murine IgG antibody mediate macrophage phagocytosis and lysis of erythrocytes.
JPH01501388A (ja) 標的細胞の死滅を目的とするエフエクター細胞の生体外活性化
JPH0198478A (ja) ＩｇＧモノクローナル抗体−生産性ハイブリドマ
JPH03502762A (ja) Ｔ細胞抗原レセプターの特定の領域に対して反応性のモノクローナル抗体
LT4225B (en) Immuno-stimulatory monoclonal antibodies
Kawanishi In vitro studies on IgG-mediated lymphocyte cytotoxicity in chronic active liver disease
JPH05508663A (ja) 哺乳動物における異系移植片拒否反応を抑制するための方法と組成物
HUT61341A (en) Monoclonal antibodies for inducing tolerance
CA1340350C (en) Monoclonal antibody to the 75 kd subunit of the human interleukin-2 receptor and use thereof
Golstein et al. Specific adsorption of cytotoxic thymus‐processed lymphocytes (T cells) on glutaraldehyde‐fixed fibroblast monolayers
Kimata et al. Modulation of ongoing human immunoglobulin synthesis by natural killer cells
Carvalho et al. Characterization of a non-T, non-B human blood lymphocyte that mediates the enhancing effects of immune complexes on lymphocyte blastogenesis.
Nussenzweig et al. C3-receptor sites on leukocytes: Possible role in opsonization and in the immune response
JPS6016590A (ja) 免疫抑制因子を生産する突然変異体ヒトｔ細胞系統およびこのような突然変異体を得る方法
Rice et al. Angioimmunoblastic lymphadenopathy with hypogammaglobulinemia: Possible role of monocyte suppression
Daguillard et al. Hyperactive production of antibody of a boy with thymic dysplasia undergoing graft versus host reaction
Sager et al. Bacterial lipopolysaccharide-induced immunoglobulin synthesis by human blood lymphocytes partially depleted of monocytes
EP0501320A1 (en) Immunopotentiating drug containing an anti-testosterone antibody
EP0105749A2 (en) Compositions for use in inducing immunosuppression or immunoregulation of the immune response to an antigen
Fuson et al. Antibody--antigen complex stimulated lysis of non-sensitized sheep red cells by human lymphocytes. I. Requirements for IgG complexes